Last reviewed · How we verify
tenofovir monotherapy — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
tenofovir monotherapy (tenofovir monotherapy) — Uijeongbu St. Mary Hospital. Tenofovir inhibits HIV reverse transcriptase by competing with natural substrates and causing DNA chain termination.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| tenofovir monotherapy TARGET | tenofovir monotherapy | Uijeongbu St. Mary Hospital | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- tenofovir monotherapy CI watch — RSS
- tenofovir monotherapy CI watch — Atom
- tenofovir monotherapy CI watch — JSON
- tenofovir monotherapy alone — RSS
Cite this brief
Drug Landscape (2026). tenofovir monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/tenofovir-monotherapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing